Mukesh Verma1, Sucai Liu1, Lidia Michalec2, Anand Sripada1, Magdalena M Gorska3, Rafeul Alam4. 1. Department of Medicine, Division of Allergy & Immunology, National Jewish Health, Denver, Colo. 2. Department of Medicine, Division of Allergy & Immunology, National Jewish Health, Denver, Colo; Department of Cytobiology and Proteomics, Medical University of Lodz, Lodz, Poland. 3. Department of Medicine, Division of Allergy & Immunology, National Jewish Health, Denver, Colo; School of Medicine, University of Colorado Denver, Denver, Colo. 4. Department of Medicine, Division of Allergy & Immunology, National Jewish Health, Denver, Colo; School of Medicine, University of Colorado Denver, Denver, Colo. Electronic address: alamr@njhealth.org.
Abstract
BACKGROUND: IL-33 plays an important role in the development of experimental asthma. OBJECTIVE: We sought to study the role of the IL-33 receptor suppressor of tumorigenicity 2 (ST2) in the persistence of asthma in a mouse model. METHODS: We studied allergen-induced experimental asthma in ST2 knockout (KO) and wild-type control mice. We measured airway hyperresponsiveness by using flexiVent; inflammatory indices by using ELISA, histology, and real-time PCR; and type 2 innate lymphoid cells (ILC2s) in lung single-cell preparations by using flow cytometry. RESULTS: Airway hyperresponsiveness was increased in allergen-treated ST2 KO mice and comparable with that in allergen-treated wild-type control mice. Peribronchial and perivascular inflammation and mucus production were largely similar in both groups. Persistence of experimental asthma in ST2 KO mice was associated with an increase in levels of thymic stromal lymphopoietin (TSLP), IL-9, and IL-13, but not IL-5, in bronchoalveolar lavage fluid. Expectedly, ST2 deletion caused a reduction in IL-13+ CD4 T cells, forkhead box P3-positive regulatory T cells, and IL-5+ ILC2s. Unexpectedly, ST2 deletion led to an overall increase in innate lymphoid cells (CD45+lin-CD25+ cells) and IL-13+ ILC2s, emergence of a TSLP receptor-positive IL-9+ ILC2 population, and an increase in intraepithelial mast cell numbers in the lung. An anti-TSLP antibody abrogated airway hyperresponsiveness, inflammation, and mucus production in allergen-treated ST2 KO mice. It also caused a reduction in innate lymphoid cell, ILC2, and IL-9+ and IL-13+ ILC2 numbers in the lung. CONCLUSIONS: Genetic deletion of the IL-33 receptor paradoxically increases TSLP production, which stimulates the emergence of IL-9+ and IL-13+ ILC2s and mast cells and leads to development of chronic experimental asthma. An anti-TSLP antibody abrogates all pathologic features of asthma in this model.
BACKGROUND:IL-33 plays an important role in the development of experimental asthma. OBJECTIVE: We sought to study the role of the IL-33 receptor suppressor of tumorigenicity 2 (ST2) in the persistence of asthma in a mouse model. METHODS: We studied allergen-induced experimental asthma in ST2 knockout (KO) and wild-type control mice. We measured airway hyperresponsiveness by using flexiVent; inflammatory indices by using ELISA, histology, and real-time PCR; and type 2 innate lymphoid cells (ILC2s) in lung single-cell preparations by using flow cytometry. RESULTS:Airway hyperresponsiveness was increased in allergen-treated ST2 KO mice and comparable with that in allergen-treated wild-type control mice. Peribronchial and perivascular inflammation and mucus production were largely similar in both groups. Persistence of experimental asthma in ST2 KO mice was associated with an increase in levels of thymic stromal lymphopoietin (TSLP), IL-9, and IL-13, but not IL-5, in bronchoalveolar lavage fluid. Expectedly, ST2 deletion caused a reduction in IL-13+ CD4 T cells, forkhead box P3-positive regulatory T cells, and IL-5+ ILC2s. Unexpectedly, ST2 deletion led to an overall increase in innate lymphoid cells (CD45+lin-CD25+ cells) and IL-13+ ILC2s, emergence of a TSLP receptor-positive IL-9+ ILC2 population, and an increase in intraepithelial mast cell numbers in the lung. An anti-TSLP antibody abrogated airway hyperresponsiveness, inflammation, and mucus production in allergen-treated ST2 KO mice. It also caused a reduction in innate lymphoid cell, ILC2, and IL-9+ and IL-13+ ILC2 numbers in the lung. CONCLUSIONS: Genetic deletion of the IL-33 receptor paradoxically increases TSLP production, which stimulates the emergence of IL-9+ and IL-13+ ILC2s and mast cells and leads to development of chronic experimental asthma. An anti-TSLP antibody abrogates all pathologic features of asthma in this model.
Authors: Alissa A Chackerian; Elizabeth R Oldham; Erin E Murphy; Jochen Schmitz; Stefan Pflanz; Robert A Kastelein Journal: J Immunol Date: 2007-08-15 Impact factor: 5.422
Authors: Kate Blease; Jane M Schuh; Claudia Jakubzick; Nicholas W Lukacs; Steven L Kunkel; Bharat H Joshi; Raj K Puri; Mark H Kaplan; Cory M Hogaboam Journal: Am J Pathol Date: 2002-02 Impact factor: 4.307
Authors: Christina A Christianson; Nicholas P Goplen; Iram Zafar; Chaoyu Irvin; James T Good; Donald R Rollins; Balachandra Gorentla; Weimin Liu; Magdalena M Gorska; HongWei Chu; Richard J Martin; Rafeul Alam Journal: J Allergy Clin Immunol Date: 2015-01-21 Impact factor: 10.793
Authors: Laura McKinley; John F Alcorn; Alanna Peterson; Rachel B Dupont; Shernaaz Kapadia; Alison Logar; Adam Henry; Charles G Irvin; Jon D Piganelli; Anuradha Ray; Jay K Kolls Journal: J Immunol Date: 2008-09-15 Impact factor: 5.422
Authors: Chris Schiering; Thomas Krausgruber; Agnieszka Chomka; Anja Fröhlich; Krista Adelmann; Elizabeth A Wohlfert; Johanna Pott; Thibault Griseri; Julia Bollrath; Ahmed N Hegazy; Oliver J Harrison; Benjamin M J Owens; Max Löhning; Yasmine Belkaid; Padraic G Fallon; Fiona Powrie Journal: Nature Date: 2014-07-16 Impact factor: 49.962
Authors: Koji Iijima; Takao Kobayashi; Kenichiro Hara; Gail M Kephart; Steven F Ziegler; Andrew N McKenzie; Hirohito Kita Journal: J Immunol Date: 2014-07-11 Impact factor: 5.422
Authors: Byunghee Koh; Benjamin J Ulrich; Andrew S Nelson; Gayathri Panangipalli; Rakshin Kharwadkar; Wenting Wu; Markus M Xie; Yongyao Fu; Matthew J Turner; Sophie Paczesny; Sarath Chandra Janga; Alexander L Dent; Mark H Kaplan Journal: J Allergy Clin Immunol Date: 2020-03-13 Impact factor: 10.793
Authors: Ekaterina O Gubernatorova; Olga A Namakanova; Ekaterina A Gorshkova; Alexandra D Medvedovskaya; Sergei A Nedospasov; Marina S Drutskaya Journal: Front Immunol Date: 2021-05-18 Impact factor: 7.561
Authors: Mukesh Verma; Lidia Michalec; Anand Sripada; Jerome McKay; Kapil Sirohi; Divya Verma; Dipa Sheth; Richard Martin; Nathan Dyjack; Max A Seibold; Jennifer R Knapp; Ting-Hui Tu; Brian P O'Connor; Magdalena M Gorska; Rafeul Alam Journal: J Exp Med Date: 2021-06-02 Impact factor: 14.307
Authors: Bobby W S Li; Marjolein J W de Bruijn; Melanie Lukkes; Menno van Nimwegen; Ingrid M Bergen; Alex KleinJan; Corine H GeurtsvanKessel; Arno Andeweg; Guus F Rimmelzwaan; Rudi W Hendriks Journal: Eur J Immunol Date: 2018-06-11 Impact factor: 5.532